A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Trial Profile

A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Deudextromethorphan (Primary)
  • Indications Agitation
  • Focus Adverse reactions
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2017 Planned number of patients changed from 550 to 700.
    • 17 Apr 2017 Planned End Date changed from 1 Jul 2019 to 1 Mar 2021.
    • 17 Apr 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top